Moreover, future studies should include a combination of EZH2 inhibitors with PARP inhibitors, tyrosine kinase inhibitors, CDK4/6 inhibitors, CDK7/9 inhibitors, AKT inhibitors, MEK inhibitors, CBP/p300 inhibitors, AURKA inhibitors, or chemotherapy for aggressive AR-negative PCa or NEPC. Here, EZH2 is linked to posterior cortical atrophy.